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Abstract
Background: Malignant steroid cell tumors of the ovary are rare and frequently associated with hormonal abnormalities.
There are no guidelines on how to treat rapidly progressive Cushing’s syndrome, a medical emergency.
Case presentation: A 67-year-old white woman presented to our hospital with rapidly developing signs and symptoms
of Cushing’s syndrome secondary to a steroid-secreting tumor. Her physical and biochemical manifestations of Cushing’s
syndrome progressed, and she was not amenable to undergoing conventional chemotherapy secondary to the
debilitating effects of high cortisol. Her rapidly progressive Cushing’s syndrome ultimately led to her death,
despite aggressive medical management with spironolactone, ketoconazole, mitotane, and mifepristone.
Conclusions: We report an unusual and rare case of Cushing’s syndrome secondary to a malignant steroid cell
tumor of the ovary. The case is highlighted to discuss the complications of rapidly progressive Cushing’s syndrome, an
underreported and often unrecognized endocrine emergency, and the best available evidence for treatment.
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Background
Ectopic Cushing’s syndrome is rarely seen with ovarian tu-
mors. Steroid cell tumors are rare stromal tumors of the
ovary first defined by Scully in 1979 [1]. They account for
<0.1 % of ovarian tumors [2]. These tumors are associated
with androgenic changes in 56–77 % of cases and Cushing’s
syndrome in 6–10 % [3]. Owing to the rarity of these tu-
mors, little is known regarding best treatment. In addition,
the debilitating effects of hypercortisolism are often over-
looked and undertreated. We report a case of a patient with
a malignant steroid-secreting tumor causing rapid onset of
virilization and Cushing’s syndrome, and she was not
amenable to aggressive medical therapy.
Case presentation
A 67-year-old nulliparous white woman with no prior med-
ical history or pertinent family history presented to our
hospital with a 4-month history of hirsutism, deepening
voice, weight gain, easy bruising, hair thinning, and chest
redness. Her physical examination revealed abdominal
swelling, pedal edema, and excessive hair growth. She had
new-onset hypertension, with an elevated blood pressure of
153/78 mmHg. Initial laboratory test results revealed a
serum glucose level of 543 mg/dl (normal 70–100 mg/dl), a
potassium level of 2.5 mg/dl (normal 3.5–5 mg/dl), and a
bicarbonate level of 44.8 mEq/L (normal 24–32 mEq/L).
Her hemoglobin A1c was 9.2 %, compared with 5.4 % when
checked only 6 months prior. Further hormonal evaluation
revealed a testosterone concentration >800 ng/dl (normal
8–60 ng/dl), a dehydroepiandrosterone level of 243 ng/ml
(normal <145 ng/ml), a luteinizing hormone concentration
<0.2 IU/L (normal 15.9–54 IU/L), and a follicle-stimulating
hormone level <0.7 IU/L (normal 16.7–136.4 IU/L). The
patient’s 24-h urine cortisol was 273 μg/24 h (normal
<45 μg/24 h). Dexamethasone 1 mg failed to suppress her
morning cortisol, which was 33 mg/dl (normal <5 mg/dl).
Her aldosterone concentration was <4 ng/dl (normal
0–21 ng/dl), and her renin level was 1.2 ng/ml (normal
0.6–3.0 ng/ml). Magnetic resonance imaging (MRI) of
the her abdomen and pelvis revealed a 9.4 × 5.8 × 7.9-cm
ovarian mass with ascites and diffuse abdominal metastasis.
Ovarian hormone testing disclosed a CA-125 level of 742.6
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U/ml (normal 0–35 U/ml), an inhibin A level of 11 pg/ml
(normal <2.1 pg/ml), and an inhibin B level of 5060 pg/ml
(normal <10 pg/ml). She was started on lisinopril 10 mg,
furosemide 20 mg, hydrochlorothiazide 12.5 mg, and
potassium chloride 10 mEq daily, as well as metoprolol
25 mg twice daily.
An exploratory laparotomy of the right ovary revealed a
lobulated mass measuring 9.8 cm in its greatest dimen-
sion. The tumor extended across to the left ovary and in-
volved the bladder, periovarian tissue, anterior abdominal
wall, and cecum. Liver metastasis was also noted. Because
of the extent of the patient’s disease, a complete resection
was not attempted. A hysterectomy, bilateral salpingo-
oophorectomy, and tumor debulking were performed.
The cut surface of the tumor was orange with
hemorrhage. Histologically, polygonal cells and abundant
cytoplasm were seen, ranging from eosinophilic to
granular, with brisk mitotic activity (22 mitoses per 10
high-power fields [HPF]). The tumor demonstrated a
solid and trabecular pattern of growth and focal myxoid
stroma. Reinke crystals were absent. The tumor stained
positive for inhibin, calretinin, and MART-1 and nega-
tive for chromogranin, S-100, WT-1, CK7, and CD99.
Based on these findings, a diagnosis of ovarian steroid
cell tumor was made.
Postoperatively, the patient’s testosterone (90 ng/dl)
and urinary cortisol (656 μg/24 h) were elevated with ad-
renocorticotropic hormone (ACTH) 12 pg/ml. No prior
ACTH measurement was available. Spironolactone and
ketoconazole were started in response to hypokalemia,
edema, and high cortisol. Spironolactone was titrated up to
400 mg daily and ketoconazole to 1200 mg daily with per-
sistent hypokalemia. Mitotane 1500 mg daily and mifepris-
tone 300 mg daily were added. Disease burden continued
to progress as urine cortisol remained elevated at 1056 μg/
24 h, with refractory hypokalemia.
Complications postoperatively included wound dehis-
cence with methicillin-resistant Staphylococcus aureus
infection requiring surgical debridement and intensive
care unit admission for pneumonia. She developed delir-
ium, depression, and malnutrition. Her poor functional
status prohibited conventional chemotherapy. A decision
was made to provide comfort care, and she subsequently
died in the hospice (Table 1).
Discussion
In 1912, Harvey Cushing described a case of a young,
obese woman with thin extremities who had hirsutism,
amenorrhea, and diabetes; her disease would come to bear
Cushing’s name [4]. The most discriminating features of
Cushing’s syndrome are easy bruising, facial plethora,
proximal myopathy, and purple striae. Nonsuppressible
hypercortisolism confirms the diagnosis.
Our patient had historical and objective features suggest-
ive of Cushing’s syndrome. However, many clinical signs
and biochemical features were also suggestive of hyperan-
drogenism. Consideration of an androgen-secreting neo-
plasm was based on the patient’s plasma androgen level.
Testosterone levels >150 ng/dl or dehydroepiandrosterone
sulfate levels >700 μg/dl suggest an androgen-secreting
neoplasm [5].
Cushing’s syndrome is rarely associated with ovarian neo-
plasms. Though the incidence of Cushing’s syndrome due
to ovarian neoplasms is unknown, authors of case reports
have described mechanisms of ectopic ACTH secretion, ec-
topic production of ACTH-like peptides, corticotropin-
releasing factor, and cortisol [6, 7].
Ovarian steroid cell tumors are classified into three sub-
types: stromal luteoma, Leydig cell tumor, and steroid cell
tumor not otherwise specified (NOS). Steroid cell tumor
NOS is the most common of the three subtypes, account-
ing for 60 % of cases [2, 8]. Steroid cell tumors NOS have
an undefined lineage and cannot be categorized as either
stromal luteomas or Leydig cell tumors. The mean age at
diagnosis is 43 years, though patients have ranged from 3
to 93 years of age [9]. A case series of 63 patients reported
by Hayes and Scully documented that 94 % were unilateral
and a majority (75 %) were capable of sex steroid hormone
production. Evidence of androgen excess was seen in 56 %
of patients, estrogen excess in 6 %, and cortisol production
in 6–10 %. In adults, approximately one-fourth of steroid
cell tumors were malignant. In their original paper, Hayes
and Scully did not describe any patients as having both ex-
cess androgen and cortisol, making the case of our patient
of particular interest [2].
The clinical manifestations of steroid cell tumor NOS
are similar to both stromal luteomas and Leydig cell tu-
mors and are associated with hormonal activity and
virilization. Common virilizing findings include hirsut-
ism, acne, deep voice, and alopecia. Estrogenic effects
are not uncommon and include menorrhagia, postmeno-
pausal bleeding, and endometrial changes. Symptoms of
Cushing’s syndrome include abdominal pain, distention,
and bloating, but they are seen in only 6–10 % of cases
[1, 2, 9, 10].
The majority of steroid cell tumors have either benign
or low-grade behavior [11, 12]. Most are diagnosed at a
younger age in an early stage, are small, and are hormo-
nally inactive. Nulliparity has not been identified as an
epidemiological risk factor for steroid cell tumors. Typic-
ally, these tumors do not recur or metastasize. Therefore,
surgical resection is considered definitive treatment. Of
the steroid cell tumor cases found to be clinically malig-
nant, only 20 % showed metastatic lesions outside the
ovary at the time of surgery. When metastasis is present,
lesions are typically localized to the peritoneal cavity. Me-
tastasis is rarely found at distant sites [2, 9–11]. The liver
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lesion noted in our patient is the first in the literature, to
our knowledge.
Malignancy in steroid cell tumors is strongly suggested
by the following pathological features: two or more
mitotic figures per 10 HPF, necrosis, a diameter >7 cm,
hemorrhage, and grade 2 or 3 nuclear atypia [2]. Our
patient’s case satisfied multiple criteria for malignancy,
including necrosis, hemorrhage, atypia, mitotic features,
and a tumor diameter >7 cm.
The diagnosis is made histologically as first defined by
Scully [2]. Steroid cell tumors NOS have two types of
polygonal cells that differ by cytoplasmic appearance:
eosinophilic or vacuolated. Absence of Reinke crystals
differentiates them from Leydig tumors. The prior no-
menclature of “lipid” cell tumors was misleading because
many tumors had little lipid present [3]. The average
diameter for malignancy is 8.5 cm, and the cut surface is
yellow-orange. Microscopically, cells are polygonal, with
central nuclei and prominent nucleoli [11]. Cells are
positive for fat stains [9, 10, 12]. Our patient had gross
and microscopic findings consistent with ovarian steroid
cell tumor NOS (Figs. 1 and 2).
Immunohistochemistry aids in diagnosis, with inhibin
and calretinin differentiating sex cord-stromal from
non-sex-cord tumors. Seventy-five percent of cases are
vimentin-positive [10, 13]. Inhibin positivity classifies
the tumor as a sex cord-stromal tumor (Fig. 3). Positive
calretinin defines its steroid cell-secretory nature
(Fig. 4). Negative immunostains rule out other malig-
nancies. In our patient, negativity of WT-1 ruled out
granulosa cell tumors, and negative CK7 and CK99
ruled out a neuroectodermal origin [9–11, 13].
On imaging studies, steroid cell tumors are typically
unilateral and solid. Cystic changes or necrosis is pos-
sible. Most are small and thus frequently undetected by
ultrasound or computed tomography [14]. MRI is the
best modality for tumor identification, with high signal
intensity on T1-weighted images due to lipid content
and intense enhancement with gadolinium reflecting
high vascularity of the tumors [14].
The best treatment for patients diagnosed with steroid-
secreting ovarian sex cell tumors has not been described.
Most of these tumors are diagnosed at an early stage and
do not recur or metastasize; thus, little is known about re-
sponse to therapy, and there is no recommended standard
of care.
Treatment of advanced ovarian steroid cell tumors is pri-
marily surgical. Following cytoreductive surgery, adjuvant
Table 1 The patient’s biochemical, hormonal, and clinical profiles pre- and postoperatively
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chemotherapy is used, though no formal recommendations
have been made [10, 12, 15]. The response is typically
short-lived. Our patient was not a candidate for chemother-
apy. Her functional status was limited by her tumor burden
and, more importantly, the hormonal manifestations of un-
controlled Cushing’s syndrome.
Rapid, aggressive Cushing’s syndrome is, and should be
considered as, an “endocrine emergency.” It is a rare pres-
entation of ovarian tumors and is highlighted in the case
of our patient. Inadequately treated Cushing’s syndrome is
associated with a three- to fivefold higher mortality [16].
Prompt, aggressive treatment, with multiple agents di-
rected at both decreasing cortisol production and damp-
ening its effects on end targets, is mandated. There are
numerous agents available to meet these treatment goals.
Their mechanism of action and duration of onset are im-
portant to consider and are discussed next.
Ketoconazole is an imidazole derivative originally devel-
oped as an antifungal agent. It blocks sex steroid and corti-
sol synthesis by multiple mechanisms, including inhibiting
11β-hydroxylase, 17α-hydroxylase, and C17,20 lyase en-
zymes. It can also inhibit ACTH secretion by corticotroph
tumor cells [15, 17, 18]. Ketoconazole decreases cortisol in
80 % of patients. Urinary free cortisol is normalized in up
to 49 % of patients [18]. However, ketoconazole takes weeks
to decrease cortisol; thus, it has limited use as a single agent
in the treatment of rapidly progressive Cushing’s syndrome.
The treatment of Cushing’s syndrome is an off-label use for
ketoconazole.
Metyrapone is an 11β-hydroxylase inhibitor that blocks
the final step in cortisol synthesis: conversion of 11-
deoxycortisol to cortisol [17]. It is potent and short-acting.
Cortisol levels are decreased in 75 % of patients. Urinary
free cortisol is improved as early as 1 week following
Fig. 2 Higher-power view of Fig. 1. The cytoplasm of the tumor cells
shows variably sized clear vacuoles, representing fat material
Fig. 3 Immunohistochemical staining revealing inhibin positivity in
the tumor cells, classifying the tumor as a sex cord-stromal tumor
Fig. 4 Immunohistochemical staining revealing calretinin positivity
in the tumor cells, revealing its steroid cell-secretory nature
Fig. 1 Hematoxylin and eosin stain with characteristic microscopic
appearance and histology of steroid cell tumor not otherwise specified.
Seen are large aggregates of polygonal to round tumor cells having
distinct cell borders, central nuclei, and prominent nucleoli. Also present
are delicate fibrous bands. Reinke crystals are absent
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treatment. Data regarding the long-term efficacy of metyr-
apone remains scarce [17]. Therefore, metyrapone is used
as adjunctive therapy. Its use for treatment of Cushing’s
syndrome is an off-label use. Additionally, increased 11-
deoxycortisol levels cross-react with serum and urine im-
munoassays, resulting in elevated cortisol levels, making
accurate assessment of disease difficult [17, 18].
Mitotane is a derivative of dichlorodiphenyltrichloroeth-
ane and reduces cortisol production by blocking cholesterol
side-chain cleavage and 11β-hydroxylase [15, 17, 18]. It
stimulates CYP3A4 expression, reducing cortisol bioavail-
ability. Its full effect is not seen for 3 months. Mitotane has
demonstrated efficacy in adrenal adenocarcinoma and is
used to treat all forms of hypercortisolism, including un-
resectable Cushing’s disease. While 80 % of patients achieve
normalization of urinary markers, 60 % relapse after
therapy withdrawal [18]. Mitotane also causes changes in
hormone-binding globulin, causing total hormone mea-
surements to be inaccurate. As a result, free urinary and
serum cortisol is the best index of response [17, 18].
Mifepristone (RU-486) is the only U.S. Food and Drug
Administration-approved medication for Cushing’s syn-
drome of any cause. It is a potent glucocorticoid and
progesterone receptor antagonist, blocking cortisol at the
tissue level. The block in glucocorticoid action leads to
negative feedback at the hypothalamic-pituitary level,
resulting in a rise in ACTH and cortisol [17]. Recently pub-
lished data show clinical improvement in 87 % of patients,
with improvements in blood sugar, diastolic blood pressure,
and weight loss [19]. It is also used in severe hypercorti-
solism when the chance of surgical cure is low [17, 19].
Currently, there is no biochemical marker to monitor drug
effectiveness or assist in dose titration [15, 17].
Etomidate is an imidazole derivative used for anesthesia
induction. It reduces cortisol production by blocking chol-
esterol side-chain cleavage, aldosterone synthase, and 11β-
hydroxylase. Case reports show successful use of etomidate
as a short-term treatment in critically ill patients with
Cushing’s syndrome. It has a rapid onset of action, with
cortisol levels decreasing within 12 h [20]. As a continuous
intravenous infusion, it is an ideal option for rapid control
of hypercortisolemia. However, its use is limited to the in-
tensive care unit, where serum cortisol, potassium, and
level of sedation are closely monitored [20, 21]. More stu-
dies are needed to better elucidate the pharmacokinetics
and adverse effects of etomidate to create treatment proto-
cols. The treatment of Cushing’s syndrome is an off-label
use of etomidate.
Conclusions
The case of our patient highlights a rare coexistence of
Cushing’s syndrome and hyperandrogenemia due to a ma-
lignant steroid cell neoplasm of the ovary. Rapidly progres-
sive Cushing’s syndrome presented a unique therapeutic
challenge, with the biochemical effects of hypercortisolism
leading to rapid morbidity and mortality. When surgery
fails to reverse hypercortisolism, medical treatment can
suppress cortisol overproduction and its end-target effects,
improving clinical status.
In retrospect, a more aggressive approach using multiple
potent, short-acting agents may have improved the pa-
tient’s outcome. Careful monitoring and treatment by cli-
nicians familiar with medications’ mechanisms of action
are essential. The case of our patient underscores the need
for further research into the biology of this tumor and a
targeted approach for treating severe hypercortisolism.
This addition to the literature highlights a rare malignancy
and an unrecognized endocrine emergency.
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